Elicio Therapeutics
ELTX
24 hedge funds and large institutions have $9.8M invested in Elicio Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
335% more capital invested
Capital invested by funds: $2.25M → $9.8M (+$7.55M)
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
41% more funds holding
Funds holding: 17 → 24 (+7)
5.83% more ownership
Funds ownership: 4.21% → 10.04% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$4.89M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.42M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$588K |
| 4 |
Millennium Management
New York
|
+$404K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$283K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.12K |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.32K |
| 3 |
Citigroup
New York
|
-$1.83K |
| 4 |
JP Morgan Chase
New York
|
-$15 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citigroup
New York
| – | -$1.83K | -374 | Closed |
|
ELTX Hedge Fund Activity: Q1 2025 in Review
24 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q1 2025, worth a combined $9.8M — up 335% from $2.25M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ELTX positions and 2 closed out — a net gain of 7 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Knoll Capital Management, opening a new position worth an estimated $4.89M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.12K sold.
- 24 institutional investors held Elicio Therapeutics (ELTX) as of Q1 2025, up from 17 in Q4 2024.
- Funds reported $9.8M of Elicio Therapeutics stock for Q1 2025, up 335% quarter-over-quarter.
- 9 funds opened new Elicio Therapeutics positions in Q1 2025 and 2 closed out, a net change of +7 holders.
- The largest Elicio Therapeutics buyer in Q1 2025 was Knoll Capital Management, an estimated $4.89M added.
- The largest Elicio Therapeutics seller in Q1 2025 was Tower Research Capital (TRC), an estimated $3.12K sold.
Based on aggregated 13F filings for Q1 2025.